Fluorine (19F) MRS and MRI in biomedicine

NMR in Biomedicine

Volumn 24, Issue 2, 2011, Pages 114-129

  Ruiz Cabello, Jesús ^a,b   Barnett, Brad P ^a   Bottomley, Paul A ^a   Bulte, Jeff W M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cellular imaging; Lung ventilation; Molecular imaging; MR contrast agent; Oxygen measurement; Perfluorocarbon

Indexed keywords

CELLULAR IMAGING; LUNG VENTILATION; MOLECULAR IMAGING; MR CONTRAST AGENTS; OXYGEN MEASUREMENT; PERFLUOROCARBONS;

BIOLOGICAL ORGANS; BIOLOGY; FLUORINE; MOLECULAR OXYGEN; OXYGEN SENSORS; STEM CELLS;

MAGNETIC RESONANCE IMAGING;

5,5' DIFLUORO 1,2 BIS(2 AMINOPHENOXY)ETHANE N,N,N,N TETRAACETIC ACID; ADFEED; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BLOOD SUBSTITUTE; BRONCHODILATING AGENT; CAPECITABINE; DESFLURANE; FLOXURIDINE; FLUORINE; FLUORODEOXYGLUCOSE; FLUOROURACIL; FLUOSOL; FLUOXETINE; FLURAZEPAM; FLURBIPROFEN; FLUVOXAMINE; GEFITINIB; INHALATION ANESTHETIC AGENT; ISOFLURANE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; ORGANOFLUORINE DERIVATIVE; OXYCYTE; PERFLEXANE; PERFLUORO COMPOUND; PERFLUORODECALIN; PERFLUOROOCTYL BROMIDE; PERFLUOROTRIBUTYLAMINE; PERFLUOROTRIPROPYLAMINE; PERFLUTREN; SEVOFLURANE; SONOVUE; UNCLASSIFIED DRUG; UNINDEXED DRUG; BIOMATERIAL; DIAGNOSTIC AGENT; FLUOROCARBON;

AEROSOL; BIOMEDICINE; BLOOD; CARBON NUCLEAR MAGNETIC RESONANCE; CELL LABELING; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DEPRESSION; DIAGNOSTIC IMAGING; DRUG BRAIN LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG UPTAKE; EMULSION; FLUORINATION; FLUORINE NUCLEAR MAGNETIC RESONANCE; GAS; GEL; GENERAL ANESTHESIA; HEART; HUMAN; IMMUNOCOMPETENT CELL; INJECTION; LIQUID; LUNG; LUNG VENTILATION; MACROPHAGE; MICROVASCULATURE; MOLECULAR IMAGING; MOLECULE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHAGOCYTOSIS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REVIEW; SIGNAL NOISE RATIO; SOLUBILITY; TABLET FORMULATION; ULTRASOUND; ANIMAL; ARTICLE; MEDICINE; MOUSE; NUCLEAR MAGNETIC RESONANCE; RAT; VOLATILIZATION;

AEROSOLS; ANIMALS; BIOCOMPATIBLE MATERIALS; FLUORINE; FLUOROCARBONS; HUMANS; MAGNETIC RESONANCE IMAGING; MEDICINE; MICE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; RATS; SOLUBILITY; VOLATILIZATION;

EID: 79951840115     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1570     Document Type: Review

References (136)

1. 19F magnetic resonance imaging. J. Magn. Reson. 1977; 28: 133-136.
2. Bulte JWM. Hot spot MRI emerges from the background. Nat. Biotech. 2005; 23: 945-946.
3. Clark LC, Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science, 1966; 152: 1755-1756.
4. 19F and dissolved oxygen. Adv. Exp. Med. Biol. 1984; 180: 835-845.
5. Thomas SR. The biomedical application of fluorine-19 NMR. In Magnetic Resonance Imaging, Vol. 2, Partain CI, Patton JA, Kulkarni MV, James AEJ (eds). Saunders Co: London, 1988; 1536-1552.
6. 19F NMR. In Biological Magnetic Resonance, Berliner LJ (ed). Plenum Press: New York, 1992; 241-276.
7. London RE. In vivo NMR studies utilizing fluorinated probes. In Physiology and Biomedicine, Vol. 16, Gillies RJ (ed). Academic Press: New York, 1994; 263-277.
8. Mason RP. Transmembrane pH gradients in vivo: measurements using fluorinated vitamin B6 derivatives. Curr. Med. Chem. 1999; 6: 481-499.
9. Bachert P. Pharmacokinetics using fluorine NMR in vivo. Progr. NMR Spectr. 1998; 33: 1-56.
10. 19F NMR. Ann. NY Acad. Sci. 1987; 508: 33-47.
11. 19F-MRS studies of fluorinated drugs in humans. Adv. Drug Deliv. Rev. 2000; 41: 55-74.
12. McSheehy PMJ, Lemaire LP, Griffiths JR. Fluorine-19 MRS: application in oncology. In Encyclopedia of Nuclear Magnetic Resonance, Vol. 2, Grant DM, Harris RK (eds). Wiley: New York, 1996; 2048-2052.
13. Zhao DW, Jiang L, Mason RP. Measuring changes in tumor oxygenation. Methods Enzymol. 2004; 386: 378-418.
14. Riess JG. Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery. Artif. Cells Blood Substit. Immobil. Biotechnol. 2005; 33: 47-63.
15. Wolber J, Rowland IJ, Leach MO, Bifone A. Perfluorocarbon emulsions as intravenous delivery media for hyperpolarized xenon. Magn. Reson. Med. 1999; 41: 442-449.
16. Wolf W, Albright MJ, Silver MS, Weber H, Reichardt U, Sauer R. Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. Magn. Reson. Imaging, 1987; 5: 165-169.
17. 19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance. Curr. Med. Chem. 2005; 12: 819-848.
18. Brown JJ, Duncan JR, Heiken JP, Balfe DM, Corr AP, Mirowitz SA, Eilenberg SS, Lee JKT. Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging: use with and without glucagon. Radiology, 1991; 181: 455-460.
19. Anderson CM, Brown JJ, Balfe DM, Heiken JP, Borrello JA, Clouse RE, Pilgram TK. MR imaging of Crohn disease: use of perflubron as a gastrointestinal contrast agent. J. Magn. Reson. Imaging, 1994; 4: 491-496.
20. Flacke S, Fischer S, Scott MJ, Fuhrhop RW, Allen JS, McLean M, Winter PM, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM. Novel, MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation, 2001; 104: 1280-1285.
21. Morawski AM, Winter PM, Crowder KC, Caruthers SD, Fuhrhop RW, Scott MJ, Robertson JD, Abendschein DR, Lanza GM, Wickline SA. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn. Reson. Med. 2004; 51: 480-485.
22. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat. Biotech. 2005; 23: 983-987.
23. 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla. Invest. Radiol. 2006; 41: 305-312.
24. Janjic JM, Srinivas M, Kadayakkara DK, Ahrens ET. Self-delivering nanoemulsions for dual fluorine-19 MRI and fluorescence detection. J. Am. Chem. Soc. 2008; 130: 2832-2841.
25. Krafft MP. Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research. Adv. Drug Deliv. Rev. 2001; 47: 209-228.
26. Rafikova O, Sokolova E, Rafikov R, Nudler E. Control of plasma nitric oxide bioactivity by perfluorocarbons: physiological mechanisms and clinical implications. Circulation, 2004; 110: 3573-3580.
27. 1H] nuclear Overhauser effect and proton decoupling of 5-fluorouracil and alpha-fluoro-beta-alanine. J. Magn. Reson. B, 1995; 108: 155-164.
28. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J. Fluorinated pyrimidines. A new class of tumor inhibitory compounds. Nature, 1957; 179: 663-666.
29. Shani J, Wolf W. A model of chemotherapy response to 5-FU in sensitive versus resistant lymphocytic leukemia in mice. Cancer Res. 1977; 37: 2306-2308.
30. 19F NMR. Br. J. Cancer, 1984; 50: 113-117.
31. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N. Engl. J. Med. 1994; 331: 502-507.
32. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med. 1992; 326: 1593-1598.
33. Fu KK. Radiation therapy with 5-fluorouracil in head and neck cancer. Semin. Radiat. Oncol. 1997; 7: 274-282.
34. Party UACTW. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet, 1996; 348: 1049-1054.
35. Chakravarthy A, Abrams RA. Radiation therapy and 5-fluorouracil in pancreatic cancer. Semin. Radiat. Oncol. 1997; 7: 291-299.
36. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, Brechner RR. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet, 1994; 343: 1184-1187.
37. Wolf W, Waluch V, Presant CA. Non-invasive 19F-MRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed. 1998; 11: 380-387.
38. Martino R, Gilard V, Desmoulin F, Malet-Martino M. Fluorine-19 or phosphorus-31 NMR spectroscopy: a suitable analytical technique for quantitative in vitro metabolic studies of fluorinated or phosphorylated drugs. J. Pharm. Biomed. Analysis, 2005; 38: 871-891.
39. 19F NMR measurements of intracellular pH. In NMR Spectroscopy of Cells and Organisms, Vol. II, Gupta RK (ed). CRC Press, Inc.: Boca Ratón, FL, 1987; 55-74.
40. 19F pH indicators: fluoroanilines. Biophys. J. 1989; 55: 799-804.
41. 31P probes. NMR Biomed. 1999; 12: 495-504.
42. 19F NMR spectroscopy and imaging in vivo. In In Vivo Magnetic Resonance Spectroscopy III: In Vivo MR Spectroscopy: Potential and Limitations, Vol. 28, Diehl P, Günther H, Kosfeld R, Seelig J, (eds). Springer-Verlag Berlin 1992; 101-130
43. 19F NMR spectroscopy FEBS Lett 1994; 349: 234-238
44. 19F NMR measurement of intracellular free calcium ions in intact cells and tissues. In NMR Spectroscopy of Cells and Organisms, Vol. II, Gupta RK, (ed.). CRC Press, Inc. Boca Ratón, FL 1987; 45-53
45. Tsien RY. A non-disruptive technique for loading calcium buffers and indicators into cells. Nature, 1981; 290: 527-528.
46. 19F NMR. Cell Calcium, 1985; 6: 183-195.
47. Rinck PA. NMR-imaging von fluorhaltigen substanzen. Fortschr. Rontgenstr. 1984; 140: 239-243.
48. 6 Magn. Reson. Med. 2005; 54: 460-463.
49. Kuethe DO, Caprihan A, Gach M, Lowe IJ, Fukushima E. Imaging obstructed ventilation with NMR using inert fluorinated gases. J. Appl. Physiol. 2000; 88: 2279-2286.
50. Wolf U, Scholz A, Heussel CP, Markstaller K, Schreiber WG. Subsecond fluorine-19 MRI of the lung. Magn. Reson. Med. 2006; 55: 948-951.
51. 19F MR imaging of T1 of inert fluorinated gases. Magn. Reson. Med. 2008; 59: 739-746.
52. 6 with respiratory gas analysis. Magn. Reson .Imaging, 2009; 27: 549-556.
53. 6) gas. Magn. Reson. Med. 2001; 45: 605-613.
54. 6 composition on apparent diffusion coefficients. Respir. Physiol. Neurobiol. 2005; 148: 43-46.
55. 19F MR imaging of ventilation and diffusion in excised lungs. Magn. Reson. Med. 2005; 54: 577-585.
56. 3He and perfluorocarbon gas diffusion MRI of lungs. Progr. NMR Spectr. 2006; 48: 63-83.
57. Habib FA, Cohn SM. Blood substitutes. Curr. Opin. Anaesthesiol. 2004; 17: 139-143.
58. Spahn DR. Blood substitutes. Artificial oxygen carriers: perfluorocarbon emulsions. Crit. Care 1999; 3: R93-R97.
59. Huang MQ, Ye Q, Williams DS, Ho C. MRI of lungs using partial liquid ventilation with water-in-perfluorocarbon emulsions. Magn. Reson. Med. 2002; 48: 487-492.
60. 19F-MRI of perflubron for measurement of oxygen partial pressure in porcine lungs during partial liquid ventilation. Magn. Reson. Med. 2002; 47: 82-89.
61. Wolfson MR. Novel applications and perfluorochemical-associated drug delivery. ASAIO J. 2006; 52: 490.
62. Wauer RR, Gama de Abreu M, Rudiger M. 4th European Symposium on Perfluorocarbon Application. Eur. J. Med. Res. 2006; 11 (Suppl 1): 1-12.
63. Constantino ML, Shaffer T, Wauer RR, Rüdiger M. The 5th European Symposium of Perfluorocarbon (PFC) Application. ASAIO J. 2006; 52: 483.
64. Kandler M, der Hardt KV, Chada M, Walther J, Schoof E, Dötsch J, Rascher W. 3rd European Symposium on Perfluorocarbon Application: Aerosolization of perfluorocarbons (aerosol-PFC): options and restrictions of pulmonary administration of aersolized perfluorocarbons. Eur. J. Med. Res. 2003; 8: 168-182.
65. Schlemmer HP, Becker M, Bachert P, Dietz A, Rudat V, Vanselow B, Wollensack P, Zuna I, Knopp MV, Weidauer H, Wannenmacher M, van Kaick G. Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Cancer Res. 1999; 59: 2363-2369.
66. Ruiz-Cabello J, Walczak P, Kedziorek DA, Chacko VP, Schmieder AH, Wickline SA, Lanza GM, Bulte JW. In vivo 'hot spot' MR imaging of neural stem cells using fluorinated nanoparticles. Magn. Reson. Med. 2008; 60: 1506-1511.
67. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J. 2007; 21: 1647-1654.
68. Sotak CH, Hees PS, Huang H-N, Hung M-H, Young SW. A new perfluorocarbon for use in fluorine-19 magnetic resonance imaging and spectroscopy. Magn. Reson. Med. 1993; 29: 188-195.
69. 19F inversion-recovery echo-planar imaging of perfluoro-15-crown-5-ether. Magn. Reson. Med. 1994; 32: 88-97.
70. Lee H, Price RR, Holburn GE, Partain CL, Adams MD, Cacheris WP. In vivo fluorine-19 MR imaging: relaxation enhancement with Gd-DTPA. J. Magn. Reson. Imaging, 1994; 4: 609-613.
71. Srinivas M, Morel PA, Ernst LA, Laidlaw DH, Ahrens ET. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magn. Reson. Med. 2007; 58: 725-734.
72. 19F U-FLARE. Magn. Reson. Med. 1993; 29: 226-234.
73. 19F magnetic resonance imaging at 1.5 tesla. Magn. Reson. Imaging, 1991; 9: 101-106.
74. Ratner AV, Quay S, Muller HH, Simpson BB, Hurd R, Young SW. F-19 relaxation rate enhancement and frequency shift Gd-DTPA. Invest. Radiol. 1989; 24: 224-227.
75. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004; 17: 484-499.
76. Stuber M, Gilson WD, Schar M, Kedziorek DA, Hofmann LV, Shah S, Vonken EJ, Bulte JW, Kraitchman DL. Positive contrast visualization of iron oxide-labeled stem cells using inversion-recovery with ON-resonant water suppression (IRON). Magn. Reson. Med. 2007; 58: 1072-1077.
77. Cunningham CH, Arai T, Yang PC, McConnell MV, Pauly JM, Conolly SM. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn. Reson. Med. 2005; 53: 999-1005.
78. Zurkiya O, Hu X. Off-resonance saturation as a means of generating contrast with superparamagnetic nanoparticles. Magn. Reson. Med. 2006; 56: 726-732.
79. Janjic JM, Ahrens ET. Fluorine-containing nanoemulsions for MRI cell tracking. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009; 1: 492-501.
80. Nöth U, Morrissey SP, Deichmann R, Jung S, Adolf H, Haase A, Lutz J. Perfluoro-15-crown-5-ether labeled macrophages in adoptive transfer experimental allergic encephalomyelitis. Artif. Cells Blood Substit. Immobil. Biotechnol. 1997; 25: 243-254.
81. Flogel U, Ding Z, Hardung H, Jander S, Reichmann G, Jacoby C, Schubert R, Schrader J. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation, 2008; 118: 140-148.
82. 19F MRI. Magn. Reson. Med. 2009; 62: 747-753.
83. Stegman LD, Rehemtulla A, Beattie B, Kievit E, Lawrence TS, Blasberg RG, Tjuvajev JG, Ross BD. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. USA, 1999; 96: 9821-9826.
84. Cui W, Otten P, Li Y, Koeneman KS, Yu J, Mason RP. Novel NMR approach to assessing gene transfection: 4-fluoro-2-nitrophenyl-beta-D-galactopyranoside as a prototype reporter molecule for beta-galactosidase. Magn. Reson. Med. 2004; 51: 616-620.
85. 19F MRI. Angew. Chem. Int. Ed. Engl. 2009; 48: 3641-3643.
86. 19F contrast agent for MR image-guided drug delivery. J. Am. Chem. Soc. 2009; 131: 1380-1381.
87. 19F NMR spectroscopy study in the rat. NMR Biomed. 2003; 16: 494-502.
88. 19F and magnetization transfer imaging. Proc. Int. Soc. Magn. Reson. Med. 2006; 14: 1831.
89. 19F-MRI in vivo determination of the partial oxygen pressure in perfluorocarbon-loaded alginate capsules implanted into the peritoneal cavity and different tissues. Magn. Reson. Med. 1999; 42: 1039-1047.
90. Fraker C, Invaeradi L, Mares-Guia M, Ricordi C. Novel polymer formulations containing perfluorinated compounds for the engineering of cells and tissues for transplantation that improves cell metabolism and survival, and methods for making same. PCT/US2000/000106, Patent No. WO/2000/040252.
91. Khattak SF, Chin KS, Bhatia SR, Roberts SC. Enhancing oxygen tension and cellular function in alginate cell encapsulation devices through the use of perfluorocarbons. Biotechnol. Bioeng. 2006; 96: 156-166.
92. Rotta A, Gunnarsson B, Fuhrman B, Wiryawan B, Hernan L, Steinhorn D. Perfluorooctyl bromide (perflubron) attenuates oxidative injury to biological and nonbiological systems. Pediatr. Crit. Care Med. 2003; 4: 233-238.
93. Varani J, Hirschl R, Dame M, Johnson K. Perfluorocarbon protects lung epithelial cells from neutrophil-mediated injury in an in vitro model of liquid ventilation therapy. Shock 1996; 6: 339-344.
94. Riess JG. Overview of progress in the fluorocarbon approach to in vivo oxygen delivery. Biomat. Art. Cells Immob. Biotech. 1992; 20: 183-202.
95. Flaim SF. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif. Cells. Blood Substit. Immobil. Biotechnol. 1994; 22: 1043-1054.
96. Lowe KC. Engineering blood: synthetic substitutes from fluorinated compounds. Tissue Eng. 2003; 9: 389-399.
97. Dunster KR, Davies MW, Fraser JF. An advanced expiratory circuit for the recovery of perfluorocarbon liquid from non-saturated perfluorocarbon vapour during partial liquid ventilation: an experimental model. Biomed. Eng. Online 2006; 5: 7.
98. Poppers PJ. Hepatic drug metabolism and anesthesia. Anaesthesist, 1980; 29: 55-58.
99. Leese PT, Noveck RJ, Shorr JS, Woods CM, Flaim KE, Keipert PE. Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers. Anesth. Analg. 2000; 804-811.
100. Noveck RJ, Shannon EJ, Leese PT, Shorr JS, Flaim KE, Keipert PE, Woods CM. Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers. Anesth. Analg. 2000; 91: 812-822.
101. Gilliland FD, Mandel JS. Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins, and cholesterol: a study of occupationally exposed men. Am. J. Ind. Med. 1996; 29: 560-568.
102. Pfannkuch F, Schnoy N. [Perfluorochemical-emulsion (fluorocarbon-43) as blood gas carrier - fate of the substance after intravenous injection in rat (author's transl)]. Anaesthesist, 1979; 28: 511-516.
103. Karson CN, Newton JEO, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA. Human brain fluoxetine concentrations. J. Neuropsychiatr. Clin. Neurosci. 1993; 5: 322-329.
104. Miner CM, Davidson JRT, Potts NLS, Tupler LA, Charles HC, Krishnan RKR. Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. Biol. Psychiatry, 1995; 38: 696-698.
105. Martino R, Malet-Martino M, Gilard V. Fluorine nuclear magnetic resonance, a privileged tool for metabolic studies of fluoropyrimidine drugs. Curr. Drug. Metab. 2000; 1: 271-303.
106. 19F magnetic resonance spectroscopy. J. Invest. Dermatol. 1992; 99: 431-434.
107. 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength. Cancer Res. 2003; 63: 7609-7612.
108. 19F-nuclear magnetic resonance spectroscopy study. Psychiatry Res. 1992; 45: 95-104.
109. 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Am. J. Psychiatry, 1997; 154: 516-522.
110. Strauss WL, Unis AS, Cowan C, Dawson G, Dager SR. Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. Am. J. Psychiatry, 2002; 159: 755-760.
111. Keston M, Brocklehurst JC. Flurazepam and meprobamate: a clinical trial. Age Ageing, 1974; 3: 54-58.
112. Henry ME, Moore CM, Kaufman MJ, Michelson D, Schmidt ME, Stoddard E, Vuckevic AJ, Berreira PJ, Cohen BM, Renshaw PF. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. Am. J. Psychiatry, 2000; 157: 1506-1508.
113. Henry ME, Schmidt ME, Hennen J, Villafuerte RA, Butma ML, Tran P, Kerner LT, Cohen BM, Renshaw PF. A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: a 19-F MRS study. Neuropsychopharmacology, 2005; 30: 1576-1583.
114. Solomon B, Binns D, Roselt P, Weibe LI, McArthur GA, Cullinane C, Hicks RJ. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol. Cancer Ther. 2005; 4: 417-422.
115. Snyder WS, Cook MJ, Nasset ES, Karhausen LR, Howells GP, Tipton TH. Report of the Task Group on Reference Man. Volume ICRP Publication 23: Pergamon Press: Oxford, 1984; see Table 280-284.
116. Cohen JL, Cheirif J, Segar DS, Gillam LD, Gottdiener JS, Hausnerova E, Bruns DE. Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent: results of a phase III multicenter trial. J. Am. Coll. Cardiol. 1998; 32: 746-752.
117. Kitzman DW, Godman ME, Gillam LD, Cohen JL, Aurigemman GP, Gottdiener JS. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am. J. Cardiol. 2000; 86: 669-674.
118. Wyrwicz AM, Pszenny MH, Schofield JC, Tilman PC, Gordon RE, Martin PA. Noninvasive observations of fluorinated anesthetics in rabbit brain by fluorine-19 nuclear magnetic resonance. Science, 1983; 222: 428-430.
119. Xu Y, Tang P, Zhang W, Firestone L, Winter PM. Fluorine-19 nuclear magnetic resonance imaging and spectroscopy of sevoflurane uptake, distribution, and elimination in rat brain. Anesthesiology, 1995; 83: 766-774.
120. Menon DK. Fluorine-19 MRS: general overview and anesthesia. In Encyclopedia of Nuclear Magnetic Resonance, Harris RK (ed). Wiley: Chichester, 1995; 2052-2063.
121. 19F spin relaxation and localized spectroscopy of fluoxetine in human brain. Magn. Reson. Med. 1994; 31: 204-211.
122. Menon DK, Lockwood GG, Peden CJ, Cox IJ, Sargentoni J, Bell JD, Coutts GA, Whitwam JG. In vivo fluorine-19 magnetic resonance spectroscopy of cerebral halothane in postoperative patients: preliminary results. Magn. Reson. Med. 1993; 30: 680-684.
123. Litt L, Gonzalez-Mendez R, James TL, Sessler DI, Mills P, Chew W, Moseley M, Pereira B, Severinghaus JW, Hamilton WK. An in vivo study of halothane uptake and elimination in the rat brain with fluorine nuclear magnetic resonance spectroscopy. Anesthesiology, 1987; 67: 161-168.
124. Mills P, Sessler DI, Moseley M, Chew W, Pereira B, James TL, Litt L. An in vivo 19 Fluorine nuclear magnetic resonance study of isoflurane elimination from the rabbit brain. Anesthesiology, 1987; 67: 169-173.
125. Litt L, Lockart S, Cohen Y, Yasuda N, Kim F, Freire B, Laster M, Peterson N, Taheri S, Chang LH, Sessler DI, Moseley M, Eger EI, James TL. In vivo 19 Fluorine nuclear magnetic resonance brain studies of halothane, isoflurane, and desflurane: rapid elimination and no abundant saturable binding. Ann. NY Acad. Sci. 1991; 929: 707-724.
126. Litt L. Nuclear magnetic resonance advance: imaging fluorinated anesthetics in the brain. Anesthesiology, 1995; 83: 651-653.
127. 19F NMR study. Proc. Natl. Acad. Sci. USA, 1993; 90: 6478-6482.
128. Cosgrove DO, Blomley MJK, Eckersley RJ, Harvey C. Innovative contrast specific imaging with ultrasound. Electromedica 70, 2002; 2: 147-150.
129. Gould SA, Rosen AL, Sehgal LR, Sehgal HL, Langdale LA, Krause LM, Rice CL, Chamberlin WH, Moss GS. Fluosol-DA as a red-cell substitute in acute anemia. New Engl. J. Med. 1986; 314: 1653-1656.
130. Pisani E, Tsapis N, Paris J, Nicolas V, Cattel L, Fattal E. Polymeric nano/microcapsules of liquid perfluorocarbons for ultrasonic imaging: physical characterization. Langmuir, 2006; 2006: 4397-4402.
131. Ceckler TL, Gibson SL, Hilf R, Bryant RG. In situ assessment of tumor vascularity using fluorine NMR imaging. Magn. Reson. Med. 1990; 13: 416-433.
132. Cuignet OY, Wood BL, Chandler WL, Spiess BD. A second-generation blood substitute (perfluorodichlorooctane emulsion) generates spurious elevations in platelet counts from automated hematology analyzers. Anesth. Analg. 2000; 90: 517-522.
133. Briceno JC, Rincon IE, Velez JF, Castro I, Arcos MI, Velasquez CE. Oxygen transport and consumption during experimental cardiopulmonary bypass using oxyfluor. ASAIO J. 1999; 45: 322-327.
134. Mattrey RF. Perfluorooctylbromide: a new contrast agent for CT, sonography, and MR imaging. Am. J. Roentgenol. 1989; 152: 247-252.
135. Cyrus T, Abendschein DR, Caruthers SD, Harris TD, Glattauer V, Werkmeister JA, Ramshaw JAM, Wickline SA, Lanza GM. MR three-dimensional molecular imaging of intratumoral biomarkers with targeted nanoparticles. J. Cardiovasc. Magn. Reson. 2006; 8: 535-541.
136. Mason RP, Rodbumrung W, Antich PP. Hexafluorobenzene: a sensitive [19]F NMR indicator of tumor oxygenation. NMR Biomed. 1996; 9: 125-134.